<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080352</url>
  </required_header>
  <id_info>
    <org_study_id>2008-008692-33</org_study_id>
    <nct_id>NCT01080352</nct_id>
  </id_info>
  <brief_title>Vitamin C as an Anti-cancer Drug</brief_title>
  <official_title>Evaluation of Cytotoxicity and Genetic Changes of High Dose Vitamin C Infusions in Castration Resistant Metastatic Human Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can high dose, intravenous Vitamin C prolong life for patients with metastatic prostate&#xD;
      cancer?&#xD;
&#xD;
      Prostate cancer is the most common cancer (excluding skin cancer) in men in Denmark and the&#xD;
      Unites States. When metastatic disease is present cure is no longer possible. The main&#xD;
      treatment at this stage is castration, either surgical or medical, ending the patients&#xD;
      testosterone production and causing a temporary regression in disease activity.&#xD;
&#xD;
      Eventually, the cancer will progress, usually within 2 years from the castration, with a more&#xD;
      aggressive course and a survival of 2-3 years.&#xD;
&#xD;
      The current treatment option for the patients, who have undergone castration and have disease&#xD;
      progression, is chemotherapy with only limited gains in quality of life and survival.&#xD;
&#xD;
      This clinical study is a phase 2 study to evaluate the effects of high dose intravenous&#xD;
      vitamin c in subjects with early castration resistant prostate cancer.&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
        -  Prostate specific antigen (PSA) changes after 12 to 20 weekly vitamin c infusions&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Bone metastases changes after 12 to 20 weekly vitamin c infusions&#xD;
&#xD;
        -  Changes in bone specific alkaline phosphates, oxidative DNA-damage, PINP, NTX after 12&#xD;
           to 20 weekly vitamin c infusions&#xD;
&#xD;
        -  RNA-expression changes in prostatic tumor tissue after 12 to 20 weekly vitamin c&#xD;
           infusions&#xD;
&#xD;
        -  RNA-expression changes in lymphocytes after 12 to 20 weekly vitamin c infusions&#xD;
&#xD;
      Tertiary endpoints:&#xD;
&#xD;
        -  Pharmacokinetics of vitamin c in the elderly cancer patients&#xD;
&#xD;
      Methods and material:&#xD;
&#xD;
        -  80 subjects are included (efficacy evaluation when 20 subjects have been evaluated for&#xD;
           extension arm)&#xD;
&#xD;
        -  Each subject receives a weekly infusion of 60 grams vitamin c (in the form of ascorbate)&#xD;
           for 12 to 20 weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin C for palliative treatment:&#xD;
&#xD;
      Intravenous vitamin C has been used since the 1970's for terminally ill cancer patients&#xD;
      claiming big increases in survival time. The efficacy of the drug is questioned and no&#xD;
      randomized, controlled trial of Vitamin C's efficacy on cancer patients survival has been&#xD;
      made.&#xD;
&#xD;
      Recent results from in vitro and xenograft studies in mice has shown some promise for vitamin&#xD;
      c as a cytotoxic agent against cancer cells.&#xD;
&#xD;
      The following parameters are recorded for baseline:&#xD;
&#xD;
        -  Biomarkers (PSA, bALP, NTX, PINP)&#xD;
&#xD;
        -  Routine blood work (hgb, creatinine, p-vitamin c etc.)&#xD;
&#xD;
        -  Radio nucleotide bone scintigraphy&#xD;
&#xD;
        -  Prostate biopsies for later microarray (Affymetrix ST1.0)&#xD;
&#xD;
        -  Urine samples 8-oxo-guanine(for oxidative DNA-damage measurements)&#xD;
&#xD;
      These parameters are repeated after treatment, usually after 12 to 26 weeks after the first&#xD;
      vitamin c infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA changes after 12-20 weeks of treatment</measure>
    <time_frame>12, 20 and 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone metastases changes</measure>
    <time_frame>12, 26 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bALP changes</measure>
    <time_frame>12, 20, 26 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTX changes</measure>
    <time_frame>12, 20, 26 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PINP changes</measure>
    <time_frame>12, 20, 26 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-oxo-guanine changes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Vitamin C treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c.&#xD;
5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid (Vitamin C)</intervention_name>
    <description>60grams of ascorbate given intravenous infusion in 1000ml sterile water.</description>
    <arm_group_label>Vitamin C treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Castration resistant metastatic prostate cancer (bony or visceral metastases)&#xD;
&#xD;
          -  Gleason sum &gt; 6&#xD;
&#xD;
          -  PSA &gt; 10 ng/ml&#xD;
&#xD;
          -  ECOG &lt; 3&#xD;
&#xD;
          -  Prior orchidectomy or LHRH antagonist/agonist treatment&#xD;
&#xD;
          -  Must give informed content&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Synchronous active cancer (skin cancer excluded)&#xD;
&#xD;
          -  Prior chemotherapy&#xD;
&#xD;
          -  History of oxalate renal stones&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase deficiency&#xD;
&#xD;
          -  Impaired renal function (creatinine &gt; 200micromoles/L&#xD;
&#xD;
          -  Haemochromatosis&#xD;
&#xD;
          -  Cardiac disease (NYHA &gt; 2, CSS &gt; 2, recent AMI (less than 6 months)&#xD;
&#xD;
          -  Recent major surgery (less than 4 weeks before inclusion and more than 2 days of&#xD;
             admittance time)&#xD;
&#xD;
          -  Prior intended curative treatment of prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kari J Mikines, MD, DsMC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital at Herlev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departmen of Urology, Copenhagen University Hospital at Herlev</name>
      <address>
        <city>Herlev</city>
        <state>DK</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 3, 2010</study_first_submitted>
  <study_first_submitted_qc>March 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>palliative care</keyword>
  <keyword>antioxidants</keyword>
  <keyword>ascorbic acid</keyword>
  <keyword>rna expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

